Community oncologists will now have access to comprehensive tests to
help them make better informed clinical decisions aimed at personalizing
care for their patients
Partnership further expands availability of molecular profiling test
internationally
CULVER CITY, Calif. & MILAN--(BUSINESS WIRE)--
NantHealth,
Inc., (Nasdaq: NH), a leading next-generation, evidence-based,
personalized healthcare company, today announced that it has entered
into an exclusive reseller agreement for GPS
Cancer tests with Sorgente,
the market leader in biobank, stem cell and now molecular profiling
testing in Italy. The molecular tests help guide the decisions made by
oncologists for a patient’s treatment strategy including choice of
standard chemotherapy. The launch of this partnership comes on the heels
of the kick-off of the XVIII
Congresso Nazionale Aiom, (National Congress of the Italian
Association of Medical Oncology), which took place in Rome, October 28-30th at
the Marriott Park Hotel.
“As momentum continues to build not only nationally for GPS Cancer
tests, but internationally as well, we’re excited to bring Sorgente
onboard as our exclusive distributor of the test throughout Italy,” said
Patrick Soon-Shiong, MD, CEO of NantHealth. “For a country with a
population of nearly 60 million people, Italy makes up one of the top 25
countries for cancer diagnosis. In 2016 in Italy alone, 176,200 women
were diagnosed with cancer while there were 189,600 new diagnoses for
men; this disease is touching the lives of so many worldwide and we’re
excited at the possibilities GPS Cancer tests offer in terms of
personalizing treatment options – something the industry is striving
towards. Through this partnership, we’re able to offer Italian
physicians the ability to make better informed decisions about treatment
options for cancer patients – including choices for standard
chemotherapy. Oncologists are recognizing that the value of GPS lies not
only in providing insight into the responsiveness of the tumor for
therapeutic decisions, but perhaps more importantly, providing guidance
as to the presence of proteins in the tumor tissue that may indicate
resistance to standard chemotherapy and avoiding unnecessary toxicities.”
Since the launch of its commercial availability in June
2016, GPS Cancer now has an established global footprint in the
European market, which adds to the growing set of payers, providers, and
Fortune 50 companies that have already committed to covering or using
the comprehensive profiling test. Under the terms of the agreement,
Sorgente will have exclusive rights to distribute GPS Cancer to
physicians in Italy. The test, which integrates quantitative proteomics
with whole genome (DNA) and transcriptome (RNA) sequencing, is the only
integrated comprehensive molecular test of its type conducted in
CLIA-certified and CAP-accredited laboratories. It provides oncologists
with a comprehensive molecular profile of a patient’s cancer to inform
personalized treatment strategies. As a cornerstone of the Cancer
MoonShot 2020 program, GPS Cancer provides key insights based on the
unique biology of a patient’s tumor—from the DNA to the RNA to the
protein. This rich information helps doctors build more effective
treatment plans based on FDA-approved drugs and active clinical trials,
while enabling cancer researchers to design new clinical trials that
harness the potential of the immune system.
“As Sorgente has traditionally been focused on providing the best
services in umbilical cord blood banking and in genetic testing, the
opportunity to partner with NantHealth for its GPS Cancer molecular
profiling tests is an exciting one as we expand our mission of bringing
healthcare providers the best and most advanced tools to treat
patients,” said Marco Dotto, project manager for the oncology department
in Sorgente Genetica. “In 2015, it was recorded that 4.5 percent of the
Italian population was diagnosed with a tumor; this makes up a
significant portion of our country and by partnering with NantHealth,
we’re excited to bring physicians best-in-class tests that will help
treat issues related to cancer that are not only affecting so many in
Italy, but also worldwide.”
Unlike other tests on the market, GPS Cancer sequences the whole genome
of 20,000+ genes and 3 billion base pairs and matches against the
patient’s normal DNA, providing oncologists with an expansive view of
alterations to inform personalized treatment strategies. GPS Cancer
extends from genomics to proteomics not only through analysis of RNA,
but also utilizes quantitative proteomics through mass spectrometry to
measure the amounts of clinically relevant proteins that are the targets
of or essential for various therapeutics. This clinically relevant
information helps oncologists to better understand how patients may
potentially respond to chemotherapies, targeted therapies and
immunotherapies.
About NantHealth, Inc.
NantHealth, Inc. a member of the
NantWorks ecosystem of companies, is a next-generation, evidence-based,
personalized healthcare company enabling improved patient outcomes and
more effective treatment decisions for critical illnesses. NantHealth‘s
unique systems-based approach to personalized healthcare applies novel
diagnostics tailored to the specific molecular profiles of patient
tissues and integrates this molecular data in a clinical setting with
large-scale, real-time biometric signal and phenotypic data to track
patient outcomes and deliver precision medicine. For nearly a decade,
NantHealth has developed an adaptive learning system, CLINICS, which
includes its unique software, middleware and hardware systems
infrastructure that collects, indexes, analyzes and interprets billions
of molecular, clinical, operational and financial data points derived
from novel and traditional sources, continuously improves
decision-making and further optimizes our clinical pathways and decision
algorithms over time. For more information please visit www.nanthealth.com and
follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.
About GPS Cancer™
GPS Cancer™ is a unique, molecular profile
analysis available through NantHealth. GPS Cancer integrates whole
genome (DNA) sequencing, whole transcriptome (RNA) sequencing, and
quantitative proteomics through mass spectrometry, providing oncologists
with a comprehensive molecular profile of a patient’s cancer and an
assessment of protein pathway function to inform personalized treatment
strategies. GPS Cancer scanning is conducted in CLIA-certified and
CAP-accredited laboratories, and is a key enabler for Cancer MoonShot
2020, the world’s most comprehensive cancer collaborative initiative
seeking to accelerate the potential of combination immunotherapy as the
next generation standard of care in cancer patients. For more
information, visit www.gpscancer.com
and www.cancermoonshot2020.org.
About Sorgente
Sorgente is an Italian company operating in
health services with the most advanced technologies and with the highest
quality standard. Founded in 2009, the mission of Sorgente is to offer
the best service in Europe for umbilical cord blood banking and genetic
testing for the health of the whole family, Sorgente genetic tests
include non-invasive prenatal test (NIPT), hereditary diseases (as
breast cancer and thrombophilia) and food intolerance tests.
www.sorgente.com and
www.sorgentegenetica.it
Cautionary Note Concerning Forward-Looking Statements
This
press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, including, among
others, statements regarding the capabilities and anticipated utility of
our GPS Cancer, including predicting patient response and resistance to
therapeutics, enabling diagnoses by physicians and accelerating efforts
to bring novel combinations of therapeutic agents to cancer patients, as
well as our contribution to the Cancer 2020 initiative. Forward-looking
statements are subject to numerous risks and uncertainties that could
cause actual results to differ materially from currently anticipated
results. Factors that may cause future results to differ materially from
management’s current expectations include, among other things, that GPS
Cancer may not perform as anticipated, that sufficient physicians may
not adopt GPS Cancer to assist their diagnoses or that healthcare payers
may not provide reimbursement for GPS Cancer as expected. Our business
is subject to numerous additional risks and uncertainties, including,
among others, risks relating to market acceptance of our products; our
ability to successfully launch new products and applications;
competition; our sales, marketing and distribution capabilities; our
planned sales, marketing, and research and development activities;
unanticipated increases in costs or expenses; and risks associated with
international operations. Information on these and additional risks,
uncertainties, and other information affecting our business and
operating results can be found in our existing and future filings with
the Securities and Exchange Commission. These forward-looking statements
speak only as of the date hereof. We disclaim any obligation to update
these forward-looking statements except as may be required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161103005331/en/
NantWorks
Jen Hodson, 562-397-3639
jhodson@nantworks.com
Source: NantHealth, Inc.
